Our immediate former CEO reminded us at the December meeting in SLC that DE had sold a company previously and had made a tidy sum for everyone. I will remind everyone that DE also was in charge of operations of that other company at the time. What shareholders receive ultimately from Medizone depends on what kind of value can be created for the company. Right now the marketplace, in spite of all the current good news, tells us it's worth fourteen cents per share. Market research, a true business plan, demonstrations (aka testing), sales penetration in multiple markets, and a relentless staff pursuing merger partners, will tell the tale.